ABT
Abbott Laboratories
Abbott Laboratories historical holders
total: 13
Sanders Capital Abbott Laboratories transactions over time
- Total transactions:
- 11
- New positions:
- 1
- Added:
- 2
- Reduced:
- 8
- Held since:
- 2023 Q4
- Held for:
- 11 quarters
- Latest activity:
- 2026 Q2
Lewis Sanders has been an institutional investor in Abbott Laboratories (ABT) since 2023 Q4. According to 2026 Q2 report, Lewis Sanders holds 1,050,405 shares with a market value of roughly $95.31M representing 0.10% of their equity portfolio. The fund/company first acquired ABT in 2023 Q4, initially purchasing about 1.19M shares. Since the initial investment, Sanders Capital has made 10 more transactions in this position.
Does Lewis Sanders still hold ABT?
Yes, Lewis Sanders continues to hold Abbott Laboratories (ABT). According to their 2026 Q2 report, they maintain a position of 1,050,405 shares valued at approximately $95.31M, representing 0.10% of their equity portfolio.
When did Lewis Sanders first invest in ABT?
Lewis Sanders first invested in Abbott Laboratories (ABT) in 2023 Q4 at the reported quarter-end price of $110.07 per share, acquiring 1,193,078 shares in their initial purchase.
What is Lewis Sanders's average cost basis for ABT?
Based on historical transaction data, Lewis Sanders's estimated cost basis for Abbott Laboratories (ABT) is approximately $110.07 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $110.07
- Weighted AVG sell price:
- $104.37
ABT transactions history by Sanders Capital
11 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
0.10%
|
1,050,405
|
$90.74
|
$95,313,750
|
-6.31% (-70,800)
|
-0.01%
|
|
2026 Q1
|
0.14%
|
1,121,205
|
$102.67
|
$115,114,117
|
-2.64% (-30,380)
|
-0%
|
|
2025 Q4
|
0.17%
|
1,151,585
|
$125.29
|
$144,282,085
|
-2.92% (-34,660)
|
-0.01%
|
|
2025 Q3
|
0.20%
|
1,186,245
|
$133.94
|
$158,885,655
|
-0.12% (-1,450)
|
-0%
|
|
2025 Q2
|
0.22%
|
1,187,695
|
$136.01
|
$161,538,397
|
+0.10% (+1,160)
|
+0%
|
|
2025 Q1
|
0.24%
|
1,186,535
|
$132.65
|
$157,393,868
|
-0.61% (-7,276)
|
-0%
|
|
2024 Q4
|
0.20%
|
1,193,811
|
$113.11
|
$135,031,962
|
-0.11% (-1,340)
|
-0%
|
|
2024 Q3
|
0.20%
|
1,195,151
|
$114.01
|
$136,259,166
|
-0.26% (-3,097)
|
-0%
|
|
2024 Q2
|
0.19%
|
1,198,248
|
$103.91
|
$124,509,950
|
+0.44% (+5,290)
|
+0%
|
|
2024 Q1
|
0.23%
|
1,192,958
|
$113.66
|
$135,591,606
|
-0.01% (-120)
|
-0%
|
|
2023 Q4
|
0.24%
|
$110.07
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.